New precision approach against Coronavirus: scientists from the IIT, Sant'Anna School, University of Milan signed the study in the journal "Pharmacological Research", which has already led to the registration of the patent, the first step towards the drug
A new precision strategy to hinder the infection of the coronavirus and its rapid spread between cells will come from Italian scientific research, destined to be the basis of a new drug, for which a patent has already been filed. The road that will lead to the drug has started from the study sponsored by the Italian Institute of Technology, Scuola Superiore Sant'Anna (Sant’Anna School), University of Milan, now published in the journal “Pharmacological Research”, organ of the “International Union of Basic and Clinical Pharmacology”.
Scientists Paolo Ciana (University of Milan, Professor of Pharmacology), Vincenzo Lionetti (Scuola Superiore Sant'Anna, Professor of Anesthesiology), Angelo Reggiani (Istituto Italiano di Tecnologia, Principal Investigator, Pharmacologist) have wondered about the possibility of preventing the progressive advancement of infection by any variant of Sars-CoV-2, blocking the ACE2 receptor, the “door” that the coronavirus uses to enter human cells. For this purpose, the scientists have patented a new approach, the first piece of what will become a drug, based on the use of a DNA aptamer, a short oligonucleotide strand, able to bind specifically to residue K353 of ACE2 making it inaccessible to the spike protein of any coronavirus. The three inventors, together with collaborators, have already identified two anti-K353 aptamers, those capable of dose-dependently inhibiting the binding of the viral spike protein to human ACE2 and thus effectively preventing cell infection.
“Thanks to this study - scientists say - it will now be possible to develop a new precision therapeutic approach to prevent Covid-19 infection in a severe form, without stimulating the immune system or having important side effects related to the most popular drugs consisting of monoclonal antibodies or other therapeutic proteins. In this sense, in fact, the potential toxicities of nucleic acids as drugs are far less than other innovative drugs such as monoclonal antibodies or other therapeutic proteins”.
Paper available HERE.
Cover Photo: Docking simulation for the identified aptamer with human ACE2. The picture represents the most stable configuration of the interaction between human ACE2 (green) with the aptamer able to block the interaction with SARS-CoV-2. (Copyright: Ciana _ Università of Milan)
Awards: CONCORDi, one of the most important European conferences on economics of innovation, awards the best paper prize to the article coauthored by Daniele Moschella. "With new technologies, higher wages without increasing within-firm inequalities"
New technologies raise wages without increasing gender or wage inequalities within the firms that adopt them. This is the main evidence of the...
SEASONAL SCHOOL, THE INTENSIVE COURSES “OF EXCELLENCE”: FROM THE PHOTONICS TO THE ETHICS OF CLIMATE CHANGE THE VARIOUS TOPICS COVERED DURING THE FIRST MONTHS OF 2022. HOW TO APPLY, ALL THE REDUCTIONS OF THE ENROLMENT FEE
The various topics covered by the 6 Seasonal Schools that will take place on the first months of 2022 include photonics, long-distance...
THE GREAT CHALLENGES OF MEDICAL ROBOTICS: HOW TECHNOLOGY, INNOVATION AND SCIENTIFIC RESEARCH HAVE CONTRIBUTED AND WILL CONTRIBUTE TO A NEW PHASE OF DEVELOPMENT IN HEALTH AND PERSONAL CARE
In robotics, but also in many high-tech disciplines, we always try to predict what will be. But knowing the history is useful to make more...